B of A Securities Initiates Coverage On Avalo Therapeutics with Buy Rating, Announces Price Target of $35

B of A Securities analyst Alec Stranahan initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Buy rating and announces Price Target of $35.